Table of Contents PART 01: Executive summary PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 06: Market segmentation by indication PART 07: Market segmentation by end-user • Diagnostic and research laboratories • Hospitals PART 08: Geographical segmentation • Genomics biomarkers market in Americas • Genomics biomarkers market in EMEA • Genomics biomarkers market in APAC PART 09: Market drivers • Increasing low-cost clinical trials in developing countries • Improving research network infrastructures • Genomics biomarker-based personalized medicine PART 10: Impact of drivers PART 11: Market challenges • Reproducibility of genomic biomarkers and tests leading to discrepancies • Delay in time from lab to market • Reimbursement challenges for genomics biomarkers-based tests PART 12: Impact of drivers and challenges PART 13: Market trends • Improvement in care delivery with advances in genomics technologies • Expansion of new business models • Development of affordable genomic biomarkers as diagnostics for tropical diseases PART 14: Vendor landscape PART 15: Key vendor analysis • Roche Diagnostics • Myriad Genetics • QIAGEN • Thermo Fisher Scientific • Bio-Rad Laboratories • Other prominent vendors PART 16: Appendix • List of abbreviations PART 17: Explore Technavio List of Exhibits Exhibit 01: Important DNA and RNA characteristics of a genomic biomarker Exhibit 02: Product offerings Exhibit 03: The biomarkers discovery strategies Exhibit 04: The value chain on genomics biomarkers Exhibit 05: Global genomics biomarkers overview Exhibit 06: Global genomics biomarkers market ($ billions) Exhibit 07: Five forces analysis Exhibit 08: Global genomics biomarkers market by indication Exhibit 09: Market scenario of genomics biomarkers in oncology Exhibit 10: Market scenario of genomics biomarkers in cardiovascular diseases Exhibit 11: Market scenario of genomics biomarkers in neurological diseases Exhibit 12: Global genomics biomarkers market share by end-user Exhibit 13: Global genomics biomarkers market by geography 2016 (% revenues) Exhibit 14: Genomics biomarkers market in Americas overview Exhibit 15: Genomics biomarkers market in Americas ($ billions) Exhibit 16: Market analysis of genomics biomarkers in Americas Exhibit 17: Genomics biomarkers market in EMEA overview Exhibit 18: Genomics biomarkers market in EMEA ($ billions) Exhibit 19: Market analysis of genomics biomarkers in EMEA Exhibit 20: Genomics biomarkers market in APAC overview Exhibit 21: Genomics biomarkers market in APAC ($ millions) Exhibit 22: Market analysis of genomics biomarkers in APAC Exhibit 23: Some of the prominent consortia for development of biomarkers Exhibit 24: Impact of drivers Exhibit 25: Criteria for acceptable biomarker-based test Exhibit 26: Impact of drivers and challenges Exhibit 27: Techniques used in arriving at single-cell biology Exhibit 28: Trends and innovators in genomic technologies Exhibit 29: Global genomics biomarkers market competitor rankings 2016 Exhibit 30: Competitive structure analysis of global genomics biomarkers market 2016 Exhibit 31: Global genomics biomarkers market-competitive landscape Exhibit 32: Game-changing strategies for market participants Exhibit 33: Roche Diagnostics strength assessment Exhibit 34: Roche Diagnostics strategy assessment Exhibit 35: Roche Diagnostics opportunity assessment Exhibit 36: Myriad Genetics strength assessment Exhibit 37: Myriad Genetics strategy assessment Exhibit 38: Myriad Genetics opportunity assessment Exhibit 39: QIAGEN strength assessment Exhibit 40: QIAGEN strategy assessment Exhibit 41: QIAGEN opportunity assessment Exhibit 42: Thermo Fisher Scientific strength assessment Exhibit 43: Thermo Fisher Scientific strategy assessment Exhibit 44: Thermo Fisher Scientific opportunity assessment Exhibit 45: Bio-Rad Laboratories strength assessment Exhibit 46: Bio-Rad Laboratories strategy assessment Exhibit 47: Bio-Rad Laboratories opportunity assessment Exhibit 48: Other prominent vendors

Roche Diagnostics, Myriad Genetics, QIAGEN, Thermo Fisher Scientific, Bio-Rad Laboratories, 23andMe, Aepodia, Almac, AROS Applied Biotechnology, DNAVision, Epigenomics, Epistem, Eurofins Scientific, Foundation Medicine, Genomic Health, Liquid Genomics, New England Biolabs, OriGene, US Biomarkers.